Pulmonx Corporation

Equities

LUNG

US7458481014

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
7.47 USD -5.32% Intraday chart for Pulmonx Corporation -10.97% -41.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pulmonx Appoints Mehul Joshi as Chief Financial Officer MT
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024 CI
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial CI
North American Morning Briefing : Traders Await -2- DJ
Pulmonx Shares Fall After Wells Fargo Downgrade MT
Wells Fargo Downgrades Pulmonx to Equalweight From Overweight, Cuts Price Target to $14 From $16 MT
Canaccord Genuity Adjusts Pulmonx's Price Target to $16 From $12, Keeps Buy Rating MT
Stifel Adjusts Pulmonx's Price Target to $17 From $15, Keeps Buy Rating MT
Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating MT
Citigroup Adjusts Pulmonx's Price Target to $17 From $16, Keeps Buy Rating MT
Craig-Hallum Adjusts Pulmonx's Price Target to $20 From $18, Keeps Buy Rating MT
Transcript : Pulmonx Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M MT
Pulmonx Corporation Provides Earnings Guidance for the Full Year 2024 CI
Pulmonx Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Pulmonx Corporation Announces Chief Executive Officer Changes, Effective March 15, 2024 CI
Pulmonx Corporation Announces Executive Changes, Effective March 15, 2024 CI
Pulmonx Insider Sold Shares Worth $292,000, According to a Recent SEC Filing MT
Transcript : Pulmonx Corporation, Q3 2023 Earnings Call, Oct 30, 2023
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q3 Revenue $17.7M, vs. Street Est of $16.7M MT
Pulmonx Corporation Provides Earnings Guidance for 2023 CI
Pulmonx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pulmonx Finance Chief Derrick Sung Leaves, John McKune Named Interim CFO; Preliminary Q3 Revenue Issued MT
Pulmonx Corporation Announces Chief Financial Officer Changes CI
Pulmonx Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2023 CI
Chart Pulmonx Corporation
More charts
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.47 USD
Average target price
16.2 USD
Spread / Average Target
+116.87%
Consensus
  1. Stock Market
  2. Equities
  3. LUNG Stock
  4. News Pulmonx Corporation
  5. Pulmonx Shares Fall After Wells Fargo Downgrade